Table of Contents
<< Previous Issue | Mar 2019 (Vol: 2019, Issue: 3) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Roche Advances Gene Therapy Investment with Spark Acquisition
-
Ipsen Boosts Rare Disease Portfolio with Clementia Acquisition
-
Biogen Jumps on Gene Therapy Train with Nightstar Acquisition
-
General Electric to Sell Biopharma Business to Danaher for US$21.4 B
- Section: Research & Development
-
AbbVie Enters Second Vectorised Antibody Partnership with Voyager Therapeutics
-
Pfizer Gains Option to Acquire Gene Therapy Specialist Vivet Therapeutics